IMRX Immuneering Corp

Price (delayed)

$1.24

Market cap

$36.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.87

Enterprise value

-$25.14M

Highlights
The debt has declined by 8% year-on-year
The EPS is up by 3.6% year-on-year
The quick ratio has increased by 26% from the previous quarter but it has decreased by 17% YoY
The gross profit has shrunk by 100% YoY
Immuneering's revenue has shrunk by 100% YoY

Key stats

What are the main financial stats of IMRX
Market
Shares outstanding
29.65M
Market cap
$36.77M
Enterprise value
-$25.14M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.46
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$54.18M
EBITDA
-$53.41M
Free cash flow
-$50.39M
Per share
EPS
-$1.87
Free cash flow per share
-$1.72
Book value per share
$2.69
Revenue per share
$0
TBVPS
$2.76
Balance sheet
Total assets
$87.98M
Total liabilities
$9.26M
Debt
$4.38M
Equity
$78.72M
Working capital
$69.27M
Liquidity
Debt to equity
0.06
Current ratio
14.38
Quick ratio
13.77
Net debt/EBITDA
1.16
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-50.5%
Return on equity
-55.8%
Return on invested capital
-222.9%
Return on capital employed
-65.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMRX stock price

How has the Immuneering stock price performed over time
Intraday
-5.34%
1 week
13.76%
1 month
-19.48%
1 year
-86.62%
YTD
-83.13%
QTD
-3.13%

Financial performance

How have Immuneering's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$59.06M
Net income
-$54.18M
Gross margin
N/A
Net margin
N/A
The gross profit has shrunk by 100% YoY
Immuneering's revenue has shrunk by 100% YoY
The operating income has declined by 10% year-on-year
The net income has declined by 6% year-on-year

Growth

What is Immuneering's growth rate over time

Valuation

What is Immuneering stock price valuation
P/E
N/A
P/B
0.46
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 3.6% year-on-year
IMRX's P/B is 78% less than its last 4 quarters average of 2.1
Immuneering's equity has decreased by 19% YoY and by 13% from the previous quarter
Immuneering's revenue has shrunk by 100% YoY

Efficiency

How efficient is Immuneering business performance
IMRX's return on invested capital has dropped by 72% year-on-year and by 10% since the previous quarter
The ROE has contracted by 26% YoY and by 6% from the previous quarter
The ROA has declined by 25% year-on-year and by 6% since the previous quarter

Dividends

What is IMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMRX.

Financial health

How did Immuneering financials performed over time
The current ratio has increased by 27% since the previous quarter but it has declined by 16% year-on-year
The quick ratio has increased by 26% from the previous quarter but it has decreased by 17% YoY
The debt is 94% smaller than the equity
IMRX's debt to equity is up by 20% since the previous quarter and by 20% year-on-year
Immuneering's equity has decreased by 19% YoY and by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.